Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 305

1.

Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.

Paumier KL, Sukoff Rizzo SJ, Berger Z, Chen Y, Gonzales C, Kaftan E, Li L, Lotarski S, Monaghan M, Shen W, Stolyar P, Vasilyev D, Zaleska M, D Hirst W, Dunlop J.

PLoS One. 2013 Aug 1;8(8):e70274. doi: 10.1371/journal.pone.0070274. Print 2013.

2.

The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease.

Wan OW, Chung KK.

PLoS One. 2012;7(6):e38545. doi: 10.1371/journal.pone.0038545. Epub 2012 Jun 12.

3.

Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes.

Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, Bruneau BG, Giasson BI, Smeyne RJ, Gershon MD, Nussbaum RL.

Hum Mol Genet. 2010 May 1;19(9):1633-50. doi: 10.1093/hmg/ddq038. Epub 2010 Jan 27.

4.

Human A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons.

Li L, Nadanaciva S, Berger Z, Shen W, Paumier K, Schwartz J, Mou K, Loos P, Milici AJ, Dunlop J, Hirst WD.

PLoS One. 2013 Dec 31;8(12):e85815. doi: 10.1371/journal.pone.0085815. eCollection 2013.

5.

Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.

Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, Lee MK.

J Neurosci. 2006 Jan 4;26(1):41-50.

6.

Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.

Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL.

Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8968-73.

7.

Chronic mild stress accelerates the progression of Parkinson's disease in A53T α-synuclein transgenic mice.

Wu Q, Yang X, Zhang Y, Zhang L, Feng L.

Exp Neurol. 2016 Nov;285(Pt A):61-71. doi: 10.1016/j.expneurol.2016.09.004. Epub 2016 Sep 13.

PMID:
27637804
8.

Generation of a alpha-synuclein-based rat model of Parkinson's disease.

Recchia A, Rota D, Debetto P, Peroni D, Guidolin D, Negro A, Skaper SD, Giusti P.

Neurobiol Dis. 2008 Apr;30(1):8-18. doi: 10.1016/j.nbd.2007.11.002. Epub 2007 Nov 13.

PMID:
18313315
9.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
10.

E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment.

Emmer KL, Waxman EA, Covy JP, Giasson BI.

J Biol Chem. 2011 Oct 7;286(40):35104-18. doi: 10.1074/jbc.M111.247965. Epub 2011 Aug 16.

11.

Neuronal expression of familial Parkinson's disease A53T α-synuclein causes early motor impairment, reduced anxiety and potential sleep disturbances in mice.

Rothman SM, Griffioen KJ, Vranis N, Ladenheim B, Cong WN, Cadet JL, Haran J, Martin B, Mattson MP.

J Parkinsons Dis. 2013;3(2):215-29. doi: 10.3233/JPD-120130.

PMID:
23938351
12.

Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.

Oaks AW, Frankfurt M, Finkelstein DI, Sidhu A.

PLoS One. 2013;8(4):e60378. doi: 10.1371/journal.pone.0060378. Epub 2013 Apr 1.

13.

Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.

Zhou W, Milder JB, Freed CR.

J Biol Chem. 2008 Apr 11;283(15):9863-70. doi: 10.1074/jbc.M710232200. Epub 2008 Jan 30.

14.

Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background.

Cabin DE, Gispert-Sanchez S, Murphy D, Auburger G, Myers RR, Nussbaum RL.

Neurobiol Aging. 2005 Jan;26(1):25-35.

PMID:
15585343
15.

alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice.

Shirakashi Y, Kawamoto Y, Tomimoto H, Takahashi R, Ihara M.

Acta Neuropathol. 2006 Dec;112(6):681-9. Epub 2006 Sep 7.

PMID:
16957925
16.

Early Parkinson's disease symptoms in α-synuclein transgenic monkeys.

Niu Y, Guo X, Chen Y, Wang CE, Gao J, Yang W, Kang Y, Si W, Wang H, Yang SH, Li S, Ji W, Li XJ.

Hum Mol Genet. 2015 Apr 15;24(8):2308-17. doi: 10.1093/hmg/ddu748. Epub 2014 Dec 30.

17.

Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.

Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T.

J Neurosci. 2011 Nov 16;31(46):16884-94. doi: 10.1523/JNEUROSCI.3967-11.2011.

18.

Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.

Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D.

Brain. 2007 Mar;130(Pt 3):799-815. Epub 2007 Feb 15.

PMID:
17303591
19.

Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.

Tatenhorst L, Eckermann K, Dambeck V, Fonseca-Ornelas L, Walle H, Lopes da Fonseca T, Koch JC, Becker S, Tönges L, Bähr M, Outeiro TF, Zweckstetter M, Lingor P.

Acta Neuropathol Commun. 2016 Apr 22;4:39. doi: 10.1186/s40478-016-0310-y.

20.

Differential regulation of wild-type and mutant alpha-synuclein binding to synaptic membranes by cytosolic factors.

Wislet-Gendebien S, Visanji NP, Whitehead SN, Marsilio D, Hou W, Figeys D, Fraser PE, Bennett SA, Tandon A.

BMC Neurosci. 2008 Sep 22;9:92. doi: 10.1186/1471-2202-9-92.

Supplemental Content

Support Center